Moderna highlights expanding mRNA platform at Science Day

Moderna's Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate. The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate. Moderna hosted its annual Science Day on 25 June. Credit: Graham Hughes/Bloomberg via Getty Images Moderna has touted the potential of its ever-expanding mRNA platform, which includes an in vivo candidate, during its annual Science Day. Held on 25 June, Moderna told participants that it will continue to broaden its mRNA platform to include infectious disease vaccines, cancer vaccines and…

Source: Clinical Trials Arena